Binding interactions of antagonists with 5-hydroxytryptamine3A receptor models.

Area of Science:

• Pharmacology
• Structural Biology
• Computational Chemistry

Background:

• The 5-hydroxytryptamine type 3A receptor (5-HT3R) is a key target for antiemetic and prokinetic drugs.
• Understanding the molecular interactions within the 5-HT3R binding site is crucial for designing more effective therapeutics.
• Previous pharmacophore models provide a framework, but detailed structural insights are lacking.

Purpose of the Study:

• To generate homology models of the N-terminal extracellular regions of human, mouse, and guinea pig 5-HT3R.
• To elucidate the molecular interactions governing the binding of 5-HT3R antagonists.
• To explain variations in antagonist potency across different species.

Main Methods:

• Homology modeling of 5-HT3R N-terminal extracellular regions using snail AChBP crystal structure.
• Molecular docking of 5-HT3R antagonists (granisetron, tropisetron, ondansetron, dolasetron, (+)-tubocurarine).
• Analysis of intra- and interface interactions, including H-bonds and salt bridges, within the pentameric structure.

Main Results:

• An aromatic binding cleft and hydrophilic vestibule were identified.
• Antagonist binding is stabilized by intercalated planar rings and interactions with specific amino acid residues (e.g., S227, E236, N128, E129, W90).
• Species-specific differences in binding cleft residues (I/S230, E229, S227) explain potency variations for certain antagonists.

Conclusions:

• The study provides a molecular basis for existing 5-HT3R antagonist pharmacophore models.
• Structural insights reveal how ligand binding affects receptor stability and interactions.
• The findings facilitate the rational design of novel 5-HT3R-targeting drugs with improved efficacy and selectivity.